Trial Profile

An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osivelotor (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions
Sponsors Global Blood Therapeutics

Most Recent Events

20 Apr 2025 Status changed from active, no longer recruiting to discontinued because data obtained from this non-placebo-controlled trial may not be informative for the interpretation of the benefits and risks of osivelotor.
03 Feb 2025 Planned End Date changed from 31 Jan 2025 to 7 Feb 2025.
03 Feb 2025 Planned primary completion date changed from 31 Jan 2025 to 7 Feb 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com